0:00 - Intro. Simon Crabb and Petros Grivas on the most interesting trials presented at ASCO GU 2022 in the field of urothelial carcinoma.
02:52 - They discuss emerging data in the neoadjuvant setting for cisplatin-ineligible patients, such as cohort H from the EV-103 trial.
06:51 - the best sequencing strategy in upper-track disease setting.
10:10 - They also review the updates on metastatic disease highlighting the longer follow-up results from JAVELIN Bladder 100 and the interesting outcomes from the ATLANTIS trial.
15:30 - In the context of the BAYOU study, they talk about the importance of patient selection and the difficulty of writing the eligibility criteria for what platinum ineligibility really means.
20:22 - They also consider how the results from TROPHY-U-01 cohort 3 support further investigation and conclude that in this rapidly evolving setting, the future relies on combination therapy.
